Greenwich LifeSciences, Inc.
GLSINASDAQHealthcare● Active
$21.65
$-0.60(-2.70%)
Market Cap$317783203
P/E Ratio—
52W High$34.1
52W Low$7.78
Greenwich LifeSciences, Inc. (GLSI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GLSI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Jun 3, 2026EPS Actual
-$0.39
Est. -$0.33 · -18.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Jun 3, 2026
After Market Close
▼ Miss EPS
GLSI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.34 | — | — | — | — | — |
| ▼ Q2 FY2026 | Jun 3, 2026 | -$0.33 | -$0.39 | -18.2% | — | — | — |
| — Q1 FY2026 | Mar 31, 2026 | -$0.32 | -$0.32 | +0.0% | $0.00B | — | — |
| — Q4 FY2025 | Nov 14, 2025 | -$0.30 | -$0.30 | +0.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.24 | -$0.30 | -25.0% | — | — | — |
| ▼ Q2 FY2025 | May 20, 2025 | -$0.24 | -$0.25 | -4.2% | — | — | — |
| ▼ Q2 FY2025 | Apr 15, 2025 | -$0.21 | -$0.61 | -190.5% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.21 | -$0.20 | +4.8% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.34
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 3, 2026Miss
EPS Actual
-$0.39
EPS Est.
-$0.33
EPS Surpr.
-18.2%
Revenue
—
Q1 FY2026
Mar 31, 2026
EPS Actual
-$0.32
EPS Est.
-$0.32
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.24
EPS Surpr.
-25.0%
Revenue
—
Q2 FY2025
May 20, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.24
EPS Surpr.
-4.2%
Revenue
—
Q2 FY2025
Apr 15, 2025Miss
EPS Actual
-$0.61
EPS Est.
-$0.21
EPS Surpr.
-190.5%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.20
EPS Est.
-$0.21
EPS Surpr.
+4.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2026 | $-0.36 | $-0.34 | $-0.30 | 1 |
| Q2 FY2026 | $-0.35 | $-0.34 | $-0.31 | 1 |
| Q1 FY2026 | $-0.35 | $-0.33 | $-0.31 | 1 |
| Q4 FY2025 | $-0.34 | $-0.32 | $-0.30 | 2 |
| Q3 FY2025 | $-0.43 | $-0.36 | $-0.28 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Jun 3, 2026 | -18.2% | $24.29 | $24.29 | +0.00% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +0.0% | $21.49 | $24.02 | +11.77% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +0.0% | $8.20 | $8.32 | +1.46% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -25.0% | $11.78 | $12.08 | +2.55% |
| ▼ Q2 FY2025 | May 20, 2025 | -4.2% | $10.18 | $10.30 | +1.18% |
| ▼ Q2 FY2025 | Apr 15, 2025 | -190.5% | $9.28 | $8.95 | -3.56% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +4.8% | $13.35 | $13.59 | +1.80% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +0.0% | $13.67 | $12.99 | -4.97% |
Q2 FY2026+0.00%
Report Date
Jun 3, 2026
EPS Beat/Miss
-18.2%
Price Before
$24.29
Price After
$24.29
Q1 FY2026+11.77%
Report Date
Mar 31, 2026
EPS Beat/Miss
+0.0%
Price Before
$21.49
Price After
$24.02
Q4 FY2025+1.46%
Report Date
Nov 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$8.20
Price After
$8.32
Q3 FY2025+2.55%
Report Date
Aug 14, 2025
EPS Beat/Miss
-25.0%
Price Before
$11.78
Price After
$12.08
Q2 FY2025+1.18%
Report Date
May 20, 2025
EPS Beat/Miss
-4.2%
Price Before
$10.18
Price After
$10.30
Q2 FY2025-3.56%
Report Date
Apr 15, 2025
EPS Beat/Miss
-190.5%
Price Before
$9.28
Price After
$8.95
Q4 FY2024+1.80%
Report Date
Nov 14, 2024
EPS Beat/Miss
+4.8%
Price Before
$13.35
Price After
$13.59
Q3 FY2024-4.97%
Report Date
Aug 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$13.67
Price After
$12.99
Avg Beat Reaction+2.52%
Avg Miss Reaction+0.04%
Beat Rate4 / 8 quarters
Largest Move+11.77% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GLSI ends December
Greenwich LifeSciences, Inc. (GLSI) most recently reported earnings on June 3, 2026 for Q2 FY2026, posting EPS of $-0.39 — missing the analyst consensus of $-0.33 by -18.2%. The next GLSI earnings date is expected around September 1, 2026.
Each quarter, investors track GLSI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GLSI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GLSI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GLSI earnings · 5 questionsGreenwich LifeSciences, Inc.'s next earnings report is expected around September 1, 2026. GLSI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GLSI historically reports after market close (AMC).
GLSI earnings datewhen is GLSI earningsGLSI next earnings datewhen does GLSI report earningsGLSI earnings calendar
▸ Source: FMP · Greenwich LifeSciences, Inc. SEC filings · US GAAP · Greenwich LifeSciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026